In addition to addressing the primary reason for the ED visit, the ED encounter may serve to reinforce healthy living, to per- form primary disease identification and prevention, to provide early disease detection (secondary prevention), to encourage and facilitate compliance with disease management, and to refer patients to primary care providers for continued management of existing disease (tertiary prevention).896,897 With the growing num- bers ofAmericans using the ED for primary care, especially socio- economically at-risk populations, the ED may present a unique opportunity to reduce cerebrovascular disease and CVD.898 Enthusiasm to use the ED as a site for initiating primary and secondary preventative services, however, must be tempered by the higher cost of providing care in this setting and per- formance pressures on the ED personnel to decrease length of stay, rates of patients who leave without treatment, overall wait times, and resource use.896,899 Although the list of potentially modifiable stroke risk factors as reviewed in this guideline is extensive, not all are amenable to assessment and initiation of preventive strategies in the ED.896 Aside from resource avail- ability, to effectively initiate primary preventive strategies, ED personnel must know the risk factors for various diseases, in this case stroke; must understand the appropriate diagnostic evaluations and definitions for the risk factors; must be aware of recommendations for appropriate interventions; and must be able to arrange primary care follow-up to assess the effect of initiated preventive interventions. Adding delivery of primary care and primary prevention to the growing list of mandated interventions delivered in the ED setting will require engaging and enabling already largely receptive ED professionals.900 ED visits serve as opportunities to screen and potentially treat patients with asymptomatic hypertension.


Adding delivery of primary care and primary prevention to the growing list of mandated interventions delivered in the ED setting will require engaging and enabling already largely receptive ED professionals.900 ED visits serve as opportunities to screen and potentially treat patients with asymptomatic hypertension. The prevalence of asymptomatic hypertension in patients presenting to the ED may be as high as 1 in 20.901 Although patients are asymptom- atic, many have target-organ injury; an ED cohort of blacks with elevated BP in the ED found that 90% had subclinical hyper- tensive heart disease.902 In ED patients with newly identified hypertension or chronically untreated hypertension, performing screening tests in the ED for target-organ damage and tests for identifiable causes of hypertension in selected patents is appro- priate. Most asymptomatic patients will not require acute BP reduction or long-term antihypertensive medication initiation in the ED. For most newly diagnosed hypertensive patients, the ED encounter can serve as a means of arranging appropriate referral Meschia et al Guidelines for the Primary Prevention of Stroke 3799 to outpatient primary care, coupled with counseling on lifestyle modifications, although this is inconsistently performed.221,903 ED personnel can identify patients with a history of hyperten- sion but nonadherence to their medication regimen who need to resume their previous medications. ED screening for hyper- tension is feasible and cost-effective. Once hypertensive patients are identified, ED personnel can educate on and encourage healthy lifestyles to address their hypertension and the impor- tance of outpatient follow-up, in accordance with the current Joint National Committee 8 outpatient guidelines.219,896,904 The incidence of diabetes mellitus has more than doubled over the last 2 decades, and millions with the condition remain undiagnosed.


Once hypertensive patients are identified, ED personnel can educate on and encourage healthy lifestyles to address their hypertension and the impor- tance of outpatient follow-up, in accordance with the current Joint National Committee 8 outpatient guidelines.219,896,904 The incidence of diabetes mellitus has more than doubled over the last 2 decades, and millions with the condition remain undiagnosed. On the basis of screening hemoglobin A1c and fasting plasma glucose, the National Health and Nutrition Examination Survey estimated the prevalence of undiagnosed diabetes mellitus in the US population to be 2.8%.905 Similar to hypertension, there is an even higher prevalence of undi- agnosed diabetes mellitus in the ED patient population.905 Although point-of-care glucose and hemoglobin A1c testing of ED patients may be feasible, it remains to be determined whether such screening is cost-effective.906 Unselected screen- ing by capillary blood glucose or hemoglobin A1c measure- ment is not currently recommended by emergency medicine societies or other healthcare agencies, but emergency physi- cians support improved recognition and referral for hyper- Patients with known diabetes mellitus commonly use EDs for acute care of complications related to diabetes mellitus, and many present with poor glycemic con- trol. These encounters provide another opportunity to encour- age medication compliance, dietary management, lifestyle modification, and outpatient follow-up.


These encounters provide another opportunity to encour- age medication compliance, dietary management, lifestyle modification, and outpatient follow-up. Despite decades of public health interventions, cigarette smoking remains a leading cause of preventable deaths in the United States, accounting for 1 of every 5 deaths each year.909 Recognizing this continuing problem, theAmerican College of Emergency Physicians recommends ED interventions aimed at smoking cessation.910 Numerous studies have demonstrated that the ED represents a promising site for smoking cessa- tion interventions through self-service kiosks and culturally appropriate literature, brief interventions, and referrals to out- With the high prevalence of smoking- related illnesses leading to ED visits, these episodes provide outstanding teachable moments to encourage cessation. The use of oral antithrombotic agents for the prevention of stroke in patients with nonvalvular AF remains a corner- stone of stroke prevention.390,913 The US National Hospital Ambulatory Medical Care Survey revealed an 88% increase in US ED visits for AF, and visits for AF are likely to increase.914 Despite ample evidence supporting anticoagulation in selected patients with AF, 12% to 34% of patients with AF presenting in the ED are eligible for warfarin but are either undertreated The ED represents an important location to identify patients with new-onset AF, to initiate anticoagula- tion depending on comorbidities, and to plan for the initial management. Similar to patients with known hypertension and diabetes mellitus, for patients with known AF, their ED encounters provide opportunities to promote behaviors to improve compliance with medication and to ensure access to Alcohol consumption is a major contributor to many ED visits.


Similar to patients with known hypertension and diabetes mellitus, for patients with known AF, their ED encounters provide opportunities to promote behaviors to improve compliance with medication and to ensure access to Alcohol consumption is a major contributor to many ED visits. In response to the epidemic of alcohol-related inju- ries and illnesses, numerous ED-based interventions have The American College of Emergency Physicians developed a brief alcohol use intervention bro- chure that does not require significant resources to produce or distribute but, by itself, was found to be only marginally effective in the absence of referral for cessation counseling.920 More interactive ED interventions require more resources but are more likely to produce enduring benefits.921 Integrating health promotion into the curriculum of emergency medicine training programs will help overcome existing nihilism of many practicing emergency physicians related to the benefit of alcohol interventions.922 Nutrition, physical activity, and drug abuse are potential lifestyle targets for behavioral interventions aimed at pri- mary stroke prevention. Of these issues, only the feasibility and efficacy of substance abuse screening and intervention have been studied in the adult ED setting, although an obe- sity screening study in a pediatric ED was recently reported, with more than half of the children being overweight or Obesity contributes to medical conditions fre- quently seen in the ED and may complicate medical inter- ventions. Many physicians are reluctant to discuss issues related to a patient s weight, and patients are not always receptive to the discussion.924 No study has investigated the use of the ED as a site for nutritional and dietary counseling.


Many physicians are reluctant to discuss issues related to a patient s weight, and patients are not always receptive to the discussion.924 No study has investigated the use of the ED as a site for nutritional and dietary counseling. Overall, although emergency physicians recognize the need for health promotion, few actually practice routine screening and counseling of emergency patients, and many are skepti- cal of the effect of ED health promotion.924 Aside from education on individual risk factors and overall healthy lifestyle promotion, the ED can serve as an effective location to educate patients about stroke signs and symptoms and the need to seek immediate medical attention. A pilot study of stroke education using educational videos was per- formed using printed stroke education materials and one-on- Compared with a control group that did not receive any intervention, the intervention group demon- strated better stroke awareness immediately after the program, but by 3 months after intervention, although statistically still more knowledgeable than the control group, test scores had declined, highlighting the need for reinforcement. The inter- vention did not affect rates of smoking or positive changes in diet and physical activity. The ED can be part of a broader sys- tem to educate and reinforce these key messages. Health care, in particular emergency care, is undergoing dramatic changes. The increasing demands for emergent and primary care will strain the capacity of many EDs to provide even basic emergency care to acutely ill patients.


The increasing demands for emergent and primary care will strain the capacity of many EDs to provide even basic emergency care to acutely ill patients. To effectively incorporate preventive services into routine ED practice, a care- ful review of feasibility and cost-effectiveness is required of each intervention, again assuming that sufficient resources are Effective primary, secondary, and tertiary stroke prevention can occur in EDs, but significant healthcare organi- zational changes are required.926 These changes must address current limitations of health promotion training for healthcare providers, program funding, resource availability, and opportu- nities for timely referral for longitudinal care. Primary Prevention in the ED: Summary and Gaps The ED may serve as an important location to provide health promotion and disease prevention services, especially during these unique teachable moments, through screening, brief inter- vention, and referral for treatment. This opportunity to identify risk factors for stroke and to begin primary prevention requires further study into resource use, efficacy, effectiveness, and cost. Primary Prevention in the ED: Recommendations 1. ED-based smoking cessation programs and interven- tions are recommended (Class I; Level of Evidence B). 2. Identification of AF and evaluation for anticoagula- tion in the ED are recommended (Class I; Level of Evidence B). 3. ED population screening for hypertension is reason- able (Class IIa; Level of Evidence C). 4. When a patient is identified as having a drug or alco- hol abuse problem, ED referral to an appropriate therapeutic program is reasonable (Class IIa; Level of Evidence C). 5. The effectiveness of screening, brief intervention, and referral for treatment of diabetes mellitus and life- style stroke risk factors (obesity, alcohol/substance abuse, sedentary lifestyle) in the ED setting is not established (Class IIb; Level of Evidence C).


The effectiveness of screening, brief intervention, and referral for treatment of diabetes mellitus and life- style stroke risk factors (obesity, alcohol/substance abuse, sedentary lifestyle) in the ED setting is not established (Class IIb; Level of Evidence C). Strategies to Improve Preventive Vascular Health Services Evidence-based guidelines are useful only if the recommen- dations translate into clinical practice.


Strategies to Improve Preventive Vascular Health Services Evidence-based guidelines are useful only if the recommen- dations translate into clinical practice. Primary vascular pre- vention approaches are underused in general practice.1,927 For example, in the United States, 6% of adults have undiag- nosed hypertension, and although the number of patients with BP treated to recommended targets has improved from 27% stantial gaps in quality remain.224,928 Opportunities to improve preventive services exist across the range of vascular risk fac- In the United States, vascular health varies substantially across the 50 states, but overall, only 3% of the adult popula- tion has ideal vascular health defined across 7 domains: hyper- tension, hyperlipidemia, smoking, BMI, diabetes mellitus, physical activity, and consumption of fruits and vegetables.929 Although preventive vascular services are a core activity of primary care physicians, specialists also have the opportunity and responsibility to identify stroke risk factors, to ensure that patients receive recommended treatments, and to encourage adherence to therapeutic interventions.930 Strategies to help cli- nicians implement guideline recommendations are often aimed at changing physician behavior related to risk factor preven- A combination of techniques is usually necessary to improve stroke preventive care, including physician education, audit and feedback of quality data, and use of checklists.931 939 Some strategies to improve stroke prevention care, although relatively costly, are more consistently effective, including electronic medical records; computer-based clinical reminder systems; and tailored, multifaceted programs.940 944 Other strate- gies focus on changing the organization or context in which the care is delivered, including delegation of preventive services to nonphysician staff (eg, nurses or pharmacists), the use of group visits, or the implementation of clinics devoted to screening and Quality improvement efforts that include activities that focus on the system, the provider, and the patient, as well as the coordination of services across these domains, are often the most effective.949 Studies examining the effectiveness of stroke education programs have generally iden- tified a modest effect on patient knowledge, risk perception, or However, studies have demonstrated the effectiveness of tailored patient self-management programs to improve vascular risk factor control.950,951 Integrated healthcare systems that have focused on improving the quality of vascu- lar prevention have demonstrated improvements in a variety of stroke risk factors at the facility or system level.952,953 Achieving sustained improvements in the quality of vascular prevention care at the system level may require multidimensional interven- tions, including implementation of electronic medical record systems, ongoing performance measurement, change in the cul- ture, and alignment of economic incentives.953,954 Stroke preven- tion services are most cost-effective for populations at increased risk (eg, patients >50 years of age).955 Preventive Health Services: Summary and Gaps Although stroke risk factor quality of care is improving, sub- stantial gaps in primary stroke prevention care exist.


The existing literature includes prospective trials and observa- tional cohorts that demonstrate the effectiveness of a vari- ety of approaches to delivering vascular prevention services. These studies have been designed to evaluate the effect of pri- mary prevention services on the control of risk factors such as hypertension, not on incident stroke rates. Quality improve- ment strategies that are multifaceted and tailored appear to be the most effective. Future research should identify the imple- mentation strategies that are associated with the greatest sus- tained improvements in preventing stroke. Preventive Health Services: Recommendation 1. It is reasonable to implement programs to systemati- cally identify and treat risk factors in all patients at risk for stroke (Class IIa; Level of Evidence A). Summary/Conclusions In this latest iteration of the guidelines, physicians and scientists should take pride in the advances that continue to be made in pre- venting stroke. Medications to control BP and lipids, anticoagu- lants for at-risk individuals with AF, revascularization, cigarette smoking cessation, diet, and exercise are among the interventions broadly applicable to the general public. With so many interven- tions, optimization of stroke prevention for individuals requires systems of care that identify risk factors as they emerge and that gain control of emerging risk factors safely, expeditiously, and cost-effectively. Access to care is necessary but not sufficient to guarantee optimal stroke prevention. Integration of inpatient and outpatient services and incentivizing efforts directed at prevent- ing stroke must also be considered. New recommendations and important revisions are summarized in Table 5. Meschia et al Guidelines for the Primary Prevention of Stroke 3801 Table 5.


Meschia et al Guidelines for the Primary Prevention of Stroke 3801 Table 5. New and Revised Recommendations for 2014* Section 2014 Recommendation Description of Change from 2011 Assessing the risk of first stroke The use of a risk assessment tool such as the AHA/ACC CV Risk Calculator (http:// my.americanheart.org/cvriskcalculator) is reasonable because these tools can help identify individuals who could benefit from therapeutic interventions and who may not be treated on the basis of any single risk factor. These calculators are useful to alert clinicians and patients of possible risk, but basing treatment decisions on the results needs to be considered in the context of the overall risk profile of the patient (Class IIa; Level of Evidence B). Reworded to add AHA/ACC CV Risk Calculator and link Genetic factors Treatment of Fabry disease with enzyme replacement therapy might be considered but has not been shown to reduce the risk of stroke, and its effectiveness is unknown (Class IIb; Level of Evidence C). Slightly reworded; no change in class or level of evidence Screening for intracranial aneurysms in every carrier of autosomal-dominant polycystic kidney disease or Ehlers-Danlos type 4 mutations is not recommended (Class III; Level of Evidence C). Previous statement was worded with less specificity, referring to mendelian disorders associated with aneurysms Pharmacogenetic dosing of vitamin K antagonists may be considered when therapy is initiated (Class IIb; Level of Evidence C). Changed from Class III (is not recommended) to Class IIb (may be considered) Physical inactivity Healthy adults should perform at least moderate- to vigorous-intensity aerobic physical activity at least 40 min a day 3 to 4 d/wk (Class I; Level of Evidence B).


Changed from Class III (is not recommended) to Class IIb (may be considered) Physical inactivity Healthy adults should perform at least moderate- to vigorous-intensity aerobic physical activity at least 40 min a day 3 to 4 d/wk (Class I; Level of Evidence B). Changed wording to match new AHA lifestyle guideline Dyslipidemia In addition to therapeutic lifestyle changes, treatment with an HMG coenzyme-A reductase inhibitor (statin) medication is recommended for primary prevention of ischemic stroke in patients estimated to have a high 10-y risk for cardiovascular events as recommended in the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (Class I; Level of Evidence A). Reworded to incorporate ACC/AHA guidelines (instead of NCEP); no change in class/LOE. Focusing on estimated cardiovascular risk as the determinant for initiating therapy is new. Niacin may be considered for patients with low high-density lipoprotein cholesterol or elevated lipoprotein(a), but its efficacy in preventing ischemic stroke in patients with these conditions is not established. Caution should be used with niacin because it increases the risk of myopathy (Class IIb; Level of Evidence B). Changed from LOE C to LOE B; the risk of myopathy is highlighted Treatment with nonstatin lipid-lowering therapies such as fibric acid derivatives, bile acid sequestrants, niacin, and ezetimibe may be considered in patients who cannot tolerate statins, but their efficacy in preventing stroke is not established (Class IIb; Level of Evidence C). Reworded from other to nonstatin (no change in class or LOE). Reference is no longer made to an low-density lipoprotein target for statin therapy because the decision to use moderate or intensive statin therapy depends on estimated risk of future cardiovascular events.


Reference is no longer made to an low-density lipoprotein target for statin therapy because the decision to use moderate or intensive statin therapy depends on estimated risk of future cardiovascular events. Diet and nutrition A Mediterranean diet supplemented with nuts may be considered in lowering the risk of stroke (Class IIb; Level of Evidence B). New recommendation Hypertension Regular blood pressure screening and appropriate treatment of patients with hypertension, including lifestyle modification and pharmacological therapy, are recommended (Class I; Level of Evidence A). Annual blood pressure screening for high blood pressure and health-promoting lifestyle modification are recommended for patients with prehypertension (systolic blood pressure of 120 139 mmHg or diastolic blood pressure of 80 89 mmHg) (Class I; Level of Evidence A). New recommendations Successful reduction of blood pressure is more important in reducing stroke risk than the choice of a specific agent, and treatment should be individualized on the basis of other patient characteristics and medication tolerance (Class I; Level of Evidence A). New recommendation Self-measured blood pressure monitoring is recommended to improve blood pressure control (Class I; Level of Evidence A) New recommendation Obesity and body fat distribution Among overweight (body mass index=25 to 29 kg/m2 ) and obese (body mass index >30 kg/m2 ) individuals, weight reduction is recommended for lowering blood pressure (Class I; Level of Evidence A). Overweight and obesity have now been defined on the basis of body mass index (Continued) Obesity and body fat distribution cont'd Among overweight (body mass index=25 to 29 kg/m2 ) and obese (body mass index >30 kg/m2 ) individuals, weight reduction is recommended for reducing the risk of stroke (Class I; Level of Evidence B).


Overweight and obesity have now been defined on the basis of body mass index (Continued) Obesity and body fat distribution cont'd Among overweight (body mass index=25 to 29 kg/m2 ) and obese (body mass index >30 kg/m2 ) individuals, weight reduction is recommended for reducing the risk of stroke (Class I; Level of Evidence B). Overweight and obesity have now been defined on the basis of body mass index, and the recommendation has been upgraded from IIa to I Diabetes mellitus Control of blood pressure in accordance with an AHA/ACC/CDC advisory to a target of <140/90 mmHg is recommended in patients with type 1 or type 2 diabetes mellitus (Class I; Level of Evidence A). Reworded to reference AHA/ACC/ CDC advisory The usefulness of aspirin for primary stroke prevention for patients with diabetes mellitus but low 10-y risk of cardiovascular disease is unclear (Class IIb; Level of Evidence B). Deleted the phrase however, administering aspirin may be reasonable Cigarette smoking Counseling in combination with drug therapy using nicotine replacement, bupropion, or varenicline is recommended for active smokers to assist in quitting smoking (Class I; Level of Evidence A). Reworded and LOE changed from B to A Community-wide or statewide bans on smoking in public spaces are reasonable for reducing the risk of stroke and myocardial infarction (Class IIa; Level of Evidence B). New recommendation Atrial fibrillation For patients with valvular atrial fibrillation at high risk for stroke, defined as a CHA2 - VASc score of 2, and acceptably low risk for hemorrhagic complications, chronic oral anticoagulant therapy with warfarin at a target INR of 2.0 to 3.0 is recommended (Class I; Level of Evidence A).


New recommendation Atrial fibrillation For patients with valvular atrial fibrillation at high risk for stroke, defined as a CHA2 - VASc score of 2, and acceptably low risk for hemorrhagic complications, chronic oral anticoagulant therapy with warfarin at a target INR of 2.0 to 3.0 is recommended (Class I; Level of Evidence A). New recommendation For patients with nonvalvular atrial fibrillation, a CHA2 -VASc score of 2, and acceptably low risk for hemorrhagic complications, oral anticoagulants are recommended (Class I). Options include warfarin (INR, 2.0 to 3.0) (Level of Evidence A), dabigatran (Level of Evidence B), apixaban (Level of Evidence B), and rivaroxaban (Level of Evidence B). The selection of antithrombotic agent should be individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time INR is in therapeutic range for patients taking warfarin. New recommendation For patients with nonvalvular atrial fibrillation and CHA2 -VASc score of 0, it is reasonable to omit antithrombotic therapy (Class IIa; Level of Evidence B). New recommendation For patients with nonvalvular atrial fibrillation, a CHA2 -VASc score of 1, and acceptably low risk for hemorrhagic complication, no antithrombotic therapy, anticoagulant therapy, or aspirin therapy may be considered (Class IIb; Level of Evidence C). The selection of antithrombotic agent should be individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time INR is in therapeutic range for patients taking warfarin.


The selection of antithrombotic agent should be individualized on the basis of patient risk factors (particularly risk for intracranial hemorrhage), cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics, including time INR is in therapeutic range for patients taking warfarin. New recommendation Closure of the left atrial appendage may be considered for high-risk patients with atrial fibrillation who are deemed unsuitable for anticoagulation if performed at a center with low rates of periprocedural complications and the patient can tolerate the risk of at least 45 d of postprocedural anticoagulation (Class IIb; Level of Evidence B). New recommendation Other cardiac conditions Anticoagulation is indicated in patients with mitral stenosis and a prior embolic event, even in sinus rhythm (Class I; Level of Evidence B). New recommendation Anticoagulation is indicated in patients with mitral stenosis and left atrial thrombus (Class I; Level of Evidence B). New recommendation Warfarin (target INR, 2.0 3.0) and low-dose aspirin are indicated after aortic valve replacement with bileaflet mechanical or current-generation, single-tilting-disk prostheses in patients with no risk factors* (Class I; Level of Evidence B); warfarin (target INR, 2.5 3.5) and low- dose aspirin are indicated in patients with mechanical aortic valve replacement and risk factors* (Class I; Level of Evidence B); and warfarin (target INR, 2.5 3.5) and low-dose aspirin are indicated after mitral valve replacement with any mechanical valve (Class I; Level of Evidence B). New recommendations Surgical excision is recommended for treatment of atrial myxomas (Class I; Level of Evidence C). New recommendation Table 5.


New recommendations Surgical excision is recommended for treatment of atrial myxomas (Class I; Level of Evidence C). New recommendation Table 5. Continued Section 2014 Recommendation Description of Change from 2011 (Continued) Meschia et al Guidelines for the Primary Prevention of Stroke 3803 Other cardiac conditions cont'd Surgical intervention is recommended for symptomatic fibroelastomas and for fibroelastomas that are >1 cm or appear mobile, even if asymptomatic (Class I; Level of Evidence C) New recommendation Aspirin is reasonable after aortic or mitral valve replacement with a bioprosthesis (Class IIa; Level of Evidence C). New recommendation It is reasonable to give warfarin to achieve an INR of 2.0 3.0 during the first 3 mo after aortic or mitral valve replacement with a bioprosthesis (Class IIa; Level of Evidence C). New recommendation Anticoagulants or antiplatelet agents are reasonable for patients with heart failure who do not have atrial fibrillation or a previous thromboembolic event (Class IIa; Level of Evidence A). New recommendation Vitamin K antagonist therapy is reasonable for patients with ST-segment elevation myocardial infarction and asymptomatic left ventricular mural thrombi (Class IIa; Level of Evidence C). The level of evidence has been downgraded from A to C, but the recommendation grade is the same Anticoagulation may be considered for asymptomatic patients with severe mitral stenosis and left atrial dimension 55 mm by echocardiography (Class IIb; Level of Evidence B). New recommendation Anticoagulation may be considered for patients with severe mitral stenosis, an enlarged left atrium, and spontaneous contrast on echocardiography (Class IIb; Level of Evidence C). New recommendation Anticoagulant therapy may be considered for patients with ST-segment elevation myocardial infarction and anterior apical akinesis or dyskinesis (Class IIb; Level of Evidence C).


New recommendation Anticoagulant therapy may be considered for patients with ST-segment elevation myocardial infarction and anterior apical akinesis or dyskinesis (Class IIb; Level of Evidence C). New recommendation Antithrombotic treatment and catheter-based closure are not recommended in patients with patent foramen ovale for primary prevention of stroke (Class III; Level of Evidence C). New recommendation Asymptomatic carotid stenosis Patients with asymptomatic carotid stenosis should be prescribed daily aspirin and a statin. Patients should also be screened for other treatable risk factors for stroke, and appropriate medical therapies and lifestyle changes should be instituted (Class I; Level of Evidence C). New recommendation. The use of aspirin and statin therapy was implied but not explicitly stated except in the perioperative and postoperative context in the prior guidelines. It is reasonable to consider performing carotid endarterectomy in asymptomatic patients who have >70% stenosis of the internal carotid artery if the risk of perioperative stroke, myocardial infarction, and death is low (<3%). However, its effectiveness compared with contemporary best medical management alone is not well established (Class IIa; Level of Evidence A). New recommendation It is reasonable to repeat duplex ultrasonography annually by a qualified technologist in a certified laboratory to assess the progression or regression of disease and response to therapeutic interventions in patients with atherosclerotic stenosis >50% (Class IIa; Level of Evidence C). New recommendation Prophylactic carotid angioplasty and stenting might be considered in highly selected patients with asymptomatic carotid stenosis (minimum, 60% by angiography, 70% by validated Doppler ultrasound), but its effectiveness compared with medical therapy alone in this situation is not well established (Class IIb; Level of Evidence B).


New recommendation Prophylactic carotid angioplasty and stenting might be considered in highly selected patients with asymptomatic carotid stenosis (minimum, 60% by angiography, 70% by validated Doppler ultrasound), but its effectiveness compared with medical therapy alone in this situation is not well established (Class IIb; Level of Evidence B). New recommendation In asymptomatic patients at high risk of complications for carotid revascularization by either carotid endarterectomy or carotid angioplasty and stenting, the effectiveness of revascularization versus medical therapy alone is not well established (Class IIb; Level of Evidence B). New recommendation Sickle cell disease Transcranial Doppler screening for children with sickle cell disease is indicated starting at 2 y of age and continuing annually to 16 y of age (Class I; Level of Evidence B). Slightly reworded to include up to 16 y (no change in class or LOE) In children at high risk for stroke who are unable or unwilling to be treated with periodic red cell transfusion, it might be reasonable to consider hydroxyurea or bone marrow transplantation (Class IIb; Level of Evidence B). Changed from LOE C to LOE B Migraine Smoking cessation should be strongly recommended in women with migraine headaches with aura (Class I; Level of Evidence B). New recommendation Alternatives to oral contraceptives, especially those containing estrogen, might be considered in women with active migraine headaches with aura (Class IIb; Level of Evidence B). New recommendation Table 5. Continued Section 2014 Recommendation Description of Change from 2011 (Continued) As health professionals, we must ensure that progress in pre- venting stroke does not lead to complacency.We must acknowl- edge that several recommendations remain vague because of suboptimal clinical trial evidence or, even more concerning, may be out of date and therefore irrelevant.


Continued Section 2014 Recommendation Description of Change from 2011 (Continued) As health professionals, we must ensure that progress in pre- venting stroke does not lead to complacency.We must acknowl- edge that several recommendations remain vague because of suboptimal clinical trial evidence or, even more concerning, may be out of date and therefore irrelevant. Diet and exercise are notoriously challenging to study with the same rigor as drugs or devices. It is easier to convince a patient to take a pill than to radically change his or her lifestyle. Nonetheless, we must expect the same standards of evidence for lifestyle interventions. Devices such as stents for carotid stenosis and occluders for PFO should be required to demonstrate favorable effects on patient-centered outcomes such as preventing stroke and not merely demonstrate favorable effects on surrogates such as expanding lumens or closing holes. The control groups of old that showed the benefits of CEA for asymptomatic stenosis would be seen as grossly undertreated medically by contemporary standards. It would be important to see if revas- cularization remains relevant in a modern context. Acknowledgments We thank medical librarians Ann Farrell at Mayo Clinic Rochester and Tara Brigham at Mayo Clinic Florida for assistance with a sys- tematic review of the medical literature. Migraine cont'd Closure of patent foramen ovale is not indicated for preventing stroke in patients with migraine (Class III; Level of Evidence B). New recommendation Drug abuse Referral to an appropriate therapeutic program is reasonable for patients who abuse drugs that have been associated with stroke, including cocaine, khat, and amphetamines (Class IIa; Level of Evidence C).


New recommendation Drug abuse Referral to an appropriate therapeutic program is reasonable for patients who abuse drugs that have been associated with stroke, including cocaine, khat, and amphetamines (Class IIa; Level of Evidence C). Wording slightly revised to specifically list drugs associated with stroke Sleep-disordered breathing Because of its association with stroke risk, screening for sleep apnea through a detailed history, including structured questionnaires such as the Epworth Sleepiness Scale and Berlin Questionnaire, physical examination, and, if indicated, polysomnography may be considered (Class IIb; Level of Evidence C). Wording slightly revised to include polysomnography and use of specific questionnaires. Recommendation class and LOE have been downgraded. Elevated lipoprotein(a) The clinical benefit of using lipoprotein(a) in stroke risk prediction is not well established (Class IIb; Level of Evidence B). New recommendation Inflammation and infection Treatment of patients with high-sensitivity C-reactive protein >2.0 mg/dL with a statin to decrease stroke risk might be considered (Class IIb; Level of Evidence B). The revised recommendation now defines elevated high-sensitivity C-reactive protein as >2.0 mg/ dL in the context of considering statin initiation Antiplatelet agents and aspirin The use of aspirin for cardiovascular (including but not specific to stroke) prophylaxis is reasonable for people whose risk is sufficiently high (10-y risk >10%) for the benefits to outweigh the risks associated with treatment. A cardiovascular risk calculator to assist in estimating 10-y risk can be found online at http://my.americanheart.org/cvriskcalculator (Class IIa; Level of Evidence A). Reworded to include cardiovascular risk calculator and link; changed from Class I to IIa Aspirin might be considered for the prevention of a first stroke in people with chronic kidney disease (ie, estimated glomerular filtration rate <45 mL min 1 ) (Class IIb; Level of Evidence C).


Reworded to include cardiovascular risk calculator and link; changed from Class I to IIa Aspirin might be considered for the prevention of a first stroke in people with chronic kidney disease (ie, estimated glomerular filtration rate <45 mL min 1 ) (Class IIb; Level of Evidence C). This recommendation does not apply to severe kidney disease (stage 4 or 5; estimated glomerular filtration rate <30 mL min 1 ). New recommendation Cilostazol may be reasonable for the prevention of a first stroke in people with peripheral arterial disease (Class IIb; Level of Evidence B). New recommendation As a result of a lack of relevant clinical trials, antiplatelet regimens other than aspirin and cilostazol are not recommended for the prevention of a first stroke (Class III; Level of Evidence C). New recommendation ACC indicates American College of Cardiology; AHA, American Heart Association; CDC, Centers for Disease Control and Prevention; CV, cardiovascular; INR, international normalized ratio; LOE, level of evidence; and NCEP, National Cholesterol Education Program. *This table does not include recommendations that have been removed. Table 5.


*This table does not include recommendations that have been removed. Table 5. Continued Section 2014 Recommendation Description of Change from 2011 Meschia et al Guidelines for the Primary Prevention of Stroke 3805 Writing Group Disclosures Writing Group Member Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other James F. Meschia Mayo Clinic NINDS None None None None None None Cheryl Bushnell Wake Forest University Baptist Medical Center World Federation of Neurology None None None None None None Bernadette Boden-Albala New York University, Global Institute of Public Health NIH None None None None None None Lynne T. Braun Rush University Medical Center NIH None None None None Nurse Practitioner Advisory Board*; UpToDate* None Dawn M. Bravata Department of Veteran Affairs Department of Veteran Affairs ; NIH/NHLBI None None None None None None Seemant Chaturvedi University of Miami Miller School of Medicine None None None None None Abbott Vascular*; Boehringer-Ingelheim*; Thornhill Research* W.L. Gore* None Mark A. Creager Brigham and Women s Hospital Medtronic ; NIH None None None None AstraZeneca ; Baxter Healthcare*; Merck (via TIMI Group)*; Novartis*; Takeda* None Robert H. Eckel University of Colorado at Denver None None None None None Amarin*; Amylin*; Genetech*; Janssen, Johnson & Johnson*; Lilly*; Novo Nordisk*; Regulus*; Sanofi-Aventis* None Mitchell S.V.


Gore* None Mark A. Creager Brigham and Women s Hospital Medtronic ; NIH None None None None AstraZeneca ; Baxter Healthcare*; Merck (via TIMI Group)*; Novartis*; Takeda* None Robert H. Eckel University of Colorado at Denver None None None None None Amarin*; Amylin*; Genetech*; Janssen, Johnson & Johnson*; Lilly*; Novo Nordisk*; Regulus*; Sanofi-Aventis* None Mitchell S.V. Elkind Columbia University BMS/Sanofi ; diaDexus, Inc NIH None None Merck Organon (Nuvaring and stroke) ; Novartis (aliskiren and stroke)* None BMS-Pfizer Pharmaceutical Partnership*; Janssen*; Daiichi Sankyo*; Biogen IDEC* None Myriam Fornage University of Texas Health Science Center at Houston None None None None None None None Larry B. Goldstein Duke University None None Pfizer* None None Daiichi Sankyo* None Steven M. Greenberg Massachusetts General Hospital NIH/NINDS None None None None None None Susanna E. Horvath Columbia University None None None None None None None Costantino Iadecola Weill Cornell Medical College None None None None None None None Edward C. Jauch Medical University of South Carolina NIH/NINDS None None None None None None Wesley S. Moore University of California at Los Angeles None None None None None None None John A. Wilson Wake Forest School of Medicine None None None None None None None This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be significant if (a) the person receives $10000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity.


A relationship is considered to be significant if (a) the person receives $10000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity. A relationship is considered to be modest if it is less than significant under the preceding definition. *Modest. Significant. Disclosures References 1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, MarelliA, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB;American HeartAssociation Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics -2014 update: a report from the American Heart Association. Circulation. 2014;129:e28 e292. 2. Heron M. Deaths: leading causes for 2007. Natl Vital Stat Rep. 2011;59:1 95. 3. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 popula- tion-based studies: a systematic review. Lancet Neurol. 2009;8:355 369. 4. Samsa GP, Matchar DB, Goldstein L, Bonito A, Duncan PW, Lipscomb J, Enarson C, Witter D, Venus P, Paul JE, Weinberger M. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998;136(pt 1):703 713. 5.


Samsa GP, Matchar DB, Goldstein L, Bonito A, Duncan PW, Lipscomb J, Enarson C, Witter D, Venus P, Paul JE, Weinberger M. Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. Am Heart J. 1998;136(pt 1):703 713. 5. Jauch EC, Saver JL,Adams HP Jr, BrunoA, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on PeripheralVascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guide- line for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2013;44:870 947. 6. Gorelick PB. Stroke prevention. Arch Neurol. 1995;52:347 355. 7. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference, IV: prevention and rehabilitation of stroke: risk factors. Stroke. 1997;28:1507 1517. 8. O Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, CzlonkowskaA, Weimar C, Wang X,Yusuf S; INTERSTROKE Investigators. Risk factors for ischaemic and intrace- rebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112 123. 9.


Risk factors for ischaemic and intrace- rebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112 123. 9. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:517 584. 10. Sacco RL. The new American Heart Association 2020 goal: achiev- ing ideal cardiovascular health. J Cardiovasc Med (Hagerstown). 2011;12:255 257. 11.


The new American Heart Association 2020 goal: achiev- ing ideal cardiovascular health. J Cardiovasc Med (Hagerstown). 2011;12:255 257. 11. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Reviewer Disclosures Reviewer Employment Research Grant Other Research Support Speakers Bureau/ Honoraria Expert Witness Ownership Interest Consultant/Advisory Board Other Kevin M. Cockroft Penn State Hershey Medical Center None None None None None Covidien Neurovascular* None Karen L. Furie Rhode Island Hospital None None None None None None None David M Greer Yale University None None None None None None None Millie Hepburn-Smith NYU Langone Medical Center None None None None None American Association of NeuroScience Nurses (member of the Board of Directors)*; National Aphasia Association (Board of Directors)* None Steven J. Kittner University of Maryland 1U01NS069208 The Stroke Genetics Network (SiGN) Study is an NINDS-funded international consortium to study the genetics of ischemic stroke and ischemic stroke Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) is an NINDS-funded study of the risk factors for intracerebral hemorrhage occurrence and outcome* None None None None None None Tatjana Rundek University of Miami None None None None None None None This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be significant if (a) the person receives $10000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity.


A relationship is considered to be significant if (a) the person receives $10000 or more during any 12-month period, or 5% or more of the person s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10000 or more of the fair market value of the entity. A relationship is considered to be modest if it is less than significant under the preceding definition. *Modest. Significant. Meschia et al Guidelines for the Primary Prevention of Stroke 3807 Miller E, Sacco RL. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009;40:2276 2293. 11a. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Pina IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545 1588. 12. Burt BA. Definitions of risk. J Dent Educ. 2001;65:1007 1008. 13. Powers BJ, Danus S, Grubber JM, Olsen MK, Oddone EZ, Bosworth HB. The effectiveness of personalized coronary heart disease and stroke risk communication. Am Heart J. 2011;161:673 680. 14. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multi- ple-risk-factor assessment equations: a statement for healthcare profes- sionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34:1348 1359. 15.


Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. AHA/ACC scientific statement: assessment of cardiovascular risk by use of multi- ple-risk-factor assessment equations: a statement for healthcare profes- sionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 1999;34:1348 1359. 15. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75 81. 16. Wolf PA, D Agostino RB, BelangerAJ, KannelWB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312 318. 17. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M, Stehouwer CD, Witteman JC, Moons KG, Bots ML. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012;308:796 803. 18. D Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk pro- file: adjustment for antihypertensive medication: the Framingham study. Stroke. 1994;25:40 43. 19. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the commu- nity: the Framingham Heart Study. JAMA. 2003;290:1049 1056. 20. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM.


2003;290:1049 1056. 20. Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM. Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study. BMJ. 2002;325:1271. 21. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S.A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol. 2002;55:129 136. 22. Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for isch- emic stroke: Dubbo Study of the elderly. Stroke. 1998;29:1341 1346. 23. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Sung FC, Chen MF, Lee YT. Constructing the prediction model for the risk of stroke in a Chinese population: report from a cohort study in Taiwan. Stroke. 2010;41:1858 1864. 24. Lackland DT, Elkind MS, D Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, McClure LA, Mitchell PH, Sacco RL, Sila CA, Smith SC Jr, Tanne D, Tirschwell DL, Touze E, Wechsler LR; on behalf of the American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research. Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1998 2027. 25. Grundy SM, D Agostino RB Sr, Mosca L, Burke GL, Wilson PW, Rader DJ, Cleeman JI, Roccella EJ, Cutler JA, Friedman LM. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation. 2001;104:491 496. 26.


Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation. 2001;104:491 496. 26. Asplund K, Karvanen J, Giampaoli S, Jousilahti P, Niemela M, Broda G, Cesana G, Dallongeville J, Ducimetriere P, Evans A, Ferrieres J, Haas B, Jorgensen T, Tamosiunas A, Vanuzzo D, Wiklund PG, Yarnell J, Kuulasmaa K, Kulathinal S; MORGAM Project. Relative risks for stroke by age, sex, and population based on follow-up of 18 European popula- tions in the MORGAM Project. Stroke. 2009;40:2319 2326. 27. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemor- rhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167 176. 28. Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, Flaherty ML, Khatri P, Ferioli S, De Los Rios La Rosa F, Broderick JP, Kleindorfer DO. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012;79:1781 1787. 29. Lee LK, Bateman BT, Wang S, Schumacher HC, Pile-Spellman J, Saposnik G. Trends in the hospitalization of ischemic stroke in the United States, 1998 2007. Int J Stroke. 2012;7:195 201. 30. Seshadri S, Beiser A, Kelly-Hayes M, Kase CS, Au R, Kannel WB, Wolf PA. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006;37:345 350. 31. Barker DJ, Lackland DT. Prenatal influences on stroke mortality in England and Wales. Stroke. 2003;34:1598 1602. 32. Lackland DT, Egan BM, Ferguson PL. Low birth weight as a risk factor for hypertension. J Clin Hypertens (Greenwich). 2003;5:133 136. 33. Johnson RC, Schoeni RF. Early-life origins of adult disease: national longitudinal population-based study of the United States. Am J Public Health. 2011;101:2317 2324. 34.


Early-life origins of adult disease: national longitudinal population-based study of the United States. Am J Public Health. 2011;101:2317 2324. 34. Lackland DT, Egan BM, Jones PJ. Impact of nativity and race on Stroke Belt mortality. Hypertension. 1999;34:57 62. 35. Cruz-Flores S, Rabinstein A, Biller J, Elkind MS, Griffith P, Gorelick PB, Howard G, Leira EC, Morgenstern LB, Ovbiagele B, Peterson E, Rosamond W, Trimble B, Valderrama AL; on behalf of the American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council on Quality of Care and Outcomes Research. Racial-ethnic disparities in stroke care: the American experi- ence: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:2091 2116. 36. Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, Woo D, Szaflarski J, Gebel J, Moomaw C, Pancioli A, Jauch E, Shukla R, Broderick J. Stroke in a biracial population: the excess burden of stroke among blacks. Stroke. 2004;35:426 431. 37. Kleindorfer D, Broderick J, Khoury J, Flaherty M, Woo D, Alwell K, Moomaw CJ, Schneider A, Miller R, Shukla R, Kissela B. The unchang- ing incidence and case-fatality of stroke in the 1990s: a population-based study. Stroke. 2006;37:2473 2478. 38. Sacco RL, Boden-Albala B, Gan R, Chen X, Kargman DE, Shea S, Paik MC, Hauser WA. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol. 1998;147:259 268. 39. Howard G, Anderson R, Sorlie P, Andrews V, Backlund E, Burke GL. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites, and blacks. The National Longitudinal Mortality Study. Stroke. 1994;25:2120 2125. 40. Morgenstern LB, Smith MA, Lisabeth LD, Risser JM, Uchino K, Garcia N, Longwell PJ, McFarling DA, Akuwumi O, Al-Wabil A, Al-Senani F, Brown DL, Moye LA.


Morgenstern LB, Smith MA, Lisabeth LD, Risser JM, Uchino K, Garcia N, Longwell PJ, McFarling DA, Akuwumi O, Al-Wabil A, Al-Senani F, Brown DL, Moye LA. Excess stroke in Mexican Americans compared with non-Hispanic Whites: the Brain Attack Surveillance in Corpus Christi Project. Am J Epidemiol. 2004;160:376 383. 41. Zahuranec DB, Brown DL, Lisabeth LD, Gonzales NR, Longwell PJ, Eden SV, Smith MA, Garcia NM, Morgenstern LB. Differences in intra- cerebral hemorrhage between Mexican Americans and non-Hispanic whites. Neurology. 2006;66:30 34. 42. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736 743. 43. Zhang Y, Galloway JM, Welty TK, Wiebers DO, Whisnant JP, Devereux RB, Kizer JR, Howard BV, Cowan LD,Yeh J, Howard WJ, Wang W, Best L, Lee ET. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation. 2008;118:1577 1584. 44. Giles WH, Kittner SJ, Hebel JR, Losonczy KG, Sherwin RW. Determinants of black-white differences in the risk of cerebral infarction: the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med. 1995;155:1319 1324. 45. Gillum RF. Risk factors for stroke in blacks: a critical review. Am J Epidemiol. 1999;150:1266 1274. 46. Kittner SJ, White LR, Losonczy KG, Wolf PA, Hebel JR. Black-white differences in stroke incidence in a national sample: the contribution of hypertension and diabetes mellitus. JAMA. 1990;264:1267 1270. 47. Liao Y, Greenlund KJ, Croft JB, Keenan NL, Giles WH. Factors explaining excess stroke prevalence in the US Stroke Belt. Stroke. 2009;40:3336 3341. 48. Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd-Jones DM.


Feinstein M, Ning H, Kang J, Bertoni A, Carnethon M, Lloyd-Jones DM. Racial differences in risks for first cardiovascular events and noncardiovascular death: the Atherosclerosis Risk in Communities study, the Cardiovascular Health Study, and the Multi-Ethnic Study of Atherosclerosis. Circulation. 2012;126:50 59. 49. Glasser SP, Judd S, Basile J, Lackland D, Halanych J, Cushman M, Prineas R, Howard V, Howard G. Prehypertension, racial prevalence and its association with risk factors: analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Am J Hypertens. 2011;24:194 199. 50. Howard VJ, Kleindorfer DO, Judd SE, McClure LA, Safford MM, Rhodes JD, Cushman M, Moy CS, Soliman EZ, Kissela BM, Howard G. Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol. 2011;69:619 627. 51. Boden-Albala B, Roberts ET, Moats H, Arif H, Sacco RL, Paik MC. Community level disadvantage and the likelihood of first ischemic stroke. Epidemiol Res Int. doi:10.1155/2012/481282. http://dx.doi. org/10.1155/2012/481282. Accessed October 4, 2014. 52. Greer S, Casper M, Kramer M, Schwartz G, Hallisey E, Holt J, Clarkson L, Zhou Y, Freymann G. Racial residential segregation and stroke mor- tality in Atlanta. Ethn Dis. 2011;21:437 443. 53. Kleindorfer D, Lindsell C, Alwell KA, Moomaw CJ, Woo D, Flaherty ML, Khatri P, Adeoye O, Ferioli S, Kissela BM. Patients living in impoverished areas have more severe ischemic strokes. Stroke. 2012;43:2055 2059. 54. Moon JR, Capistrant BD, Kawachi I, Avendano M, Subramanian SV, Bates LM, Glymour MM. Stroke incidence in older US Hispanics: is foreign birth protective? Stroke. 2012;43:1224 1229. 55. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke. 2004;35:212 227. 56.


Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke. 2004;35:212 227. 56. Seshadri S, Beiser A, Pikula A, Himali JJ, Kelly-Hayes M, Debette S, DeStefano AL, Romero JR, Kase CS, Wolf PA. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation. 2010;121:1304 1312. 57. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke. 2004;35:819 824. 58. Touze E, Rothwell PM. Sex differences in heritability of ischemic stroke: a systematic review and meta-analysis. Stroke. 2008;39:16 23. 59. Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, Farrall M, Rothwell PM, Sudlow C, Dichgans M, Markus HS. Genetic heritabil- ity of ischemic stroke and the contribution of previously reported candi- date gene and genomewide associations. Stroke. 2012;43:3161 3167. 60. Rubattu S, Stanzione R, Gigante B, Bagalino A, Musumeci B, Volpe M. Genetic susceptibility to cerebrovascular accidents. J Cardiovasc Pharmacol. 2001;38(suppl 2):S71 S74. 61. Nicolaou M, DeStefano AL, Gavras I, Cupples LA, Manolis AJ, Baldwin CT, Gavras H, Farrer LA. Genetic predisposition to stroke in relatives of hypertensives. Stroke. 2000;31:487 492. 62. Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive com- plications, and antihypertensive drug responses. Pharmacogenomics. 2003;4:53 65. 63.


Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive com- plications, and antihypertensive drug responses. Pharmacogenomics. 2003;4:53 65. 63. Falcone GJ, Biffi A, Devan WJ, Jagiella JM, Schmidt H, Kissela B, Hansen BM, Jimenez-Conde J, Giralt-Steinhauer E, Elosua R, Cuadrado- Godia E, Soriano C, Ayres AM, Schwab K, Pera J, Urbanik A, Rost NS, Goldstein JN, Viswanathan A, Pichler A, Enzinger C, Norrving B, Tirschwell DL, Selim M, Brown DL, Silliman SL, Worrall BB, Meschia JF, Kidwell CS, Montaner J, Fernandez-Cadenas I, Delgado P, Broderick JP, Greenberg SM, Roquer J, Lindgren A, Slowik A, Schmidt R, Flaherty ML, Kleindorfer DO, Langefeld CD, Woo D, Rosand J; International Stroke Genetics Consortium. Burden of risk alleles for hypertension increases risk of intracerebral hemorrhage. Stroke. 2012;43:2877 2883. 64. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K, Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S, Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH, Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491 1493. 65. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488 1491. 66.


A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488 1491. 66. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, Barrett JH, Konig IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM, Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ, Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A, Thompson JR, Schunkert H; WTCC and the Cardiogenics Consortium. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357:443 453. 67. GschwendtnerA, Bevan S, Cole JW, PlourdeA, Matarin M, Ross-Adams H, Meitinger T, Wichmann E, Mitchell BD, Furie K, Slowik A, Rich SS, Syme PD, MacLeod MJ, Meschia JF, Rosand J, Kittner SJ, Markus HS, Muller-Myhsok B, Dichgans M; International Stroke Genetics Consortium. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol. 2009;65:531 539. 68. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, Hardarson GA, Palsdottir E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, Baum L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale M, Kelly P, MacRae CA, Smith EE, Rosand J, Hillert J, Ma RC, Ellinor PT, Thorgeirsson G, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353 357. 69.


Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, Hardarson GA, Palsdottir E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, Baum L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale M, Kelly P, MacRae CA, Smith EE, Rosand J, Hillert J, Ma RC, Ellinor PT, Thorgeirsson G, Gulcher JR, Kong A, Thorsteinsdottir U, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353 357. 69. Gudbjartsson DF, Holm H, Gretarsdottir S, Thorleifsson G, Walters GB, Thorgeirsson G, Gulcher J, Mathiesen EB, Njolstad I, Nyrnes A, Wilsgaard T, Hald EM, Hveem K, Stoltenberg C, Kucera G, Stubblefield T, Carter S, Roden D, Ng MC, Baum L, So WY, Wong KS, Chan JC, Gieger C, Wichmann HE, Gschwendtner A, Dichgans M, Kuhlenbaumer G, Berger K, Ringelstein EB, Bevan S, Markus HS, Kostulas K, Hillert J, Sveinbjornsdottir S, Valdimarsson EM, Lochen ML, Ma RC, Darbar D, Kong A, Arnar DO, Thorsteinsdottir U, Stefansson K. A sequence vari- ant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet. 2009;41:876 878. 70. Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, Kostulas K, Kuhlenbaumer G, Bevan S, Jonsdottir T, Bjarnason H, Saemundsdottir J, Palsson S, Arnar DO, Holm H, Thorgeirsson G, Valdimarsson EM, Sveinbjornsdottir S, Gieger C, Berger K, Wichmann HE, Hillert J, Markus H, Gulcher JR, Ringelstein EB, KongA, Dichgans M, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008;64:402 409. 71.


Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gschwendtner A, Kostulas K, Kuhlenbaumer G, Bevan S, Jonsdottir T, Bjarnason H, Saemundsdottir J, Palsson S, Arnar DO, Holm H, Thorgeirsson G, Valdimarsson EM, Sveinbjornsdottir S, Gieger C, Berger K, Wichmann HE, Hillert J, Markus H, Gulcher JR, Ringelstein EB, KongA, Dichgans M, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol. 2008;64:402 409. 71. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, Aulchenko YS, Debette S, Lumley T, FolsomAR, van den Herik EG, Bos MJ, Beiser A, Cushman M, Launer LJ, Shahar E, Struchalin M, Du Y, Glazer NL, Rosamond WD, Rivadeneira F, Kelly-Hayes M, Lopez OL, Coresh J, Hofman A, DeCarli C, Heckbert SR, Koudstaal PJ, Yang Q, Smith NL, Kase CS, Rice K, Haritunians T, Roks G, de Kort PL, Taylor KD, de Lau LM, Oostra BA, Uitterlinden AG, Rotter JI, Boerwinkle E, Psaty BM, Mosley TH, van Duijn CM, Breteler MM, Longstreth WT Jr, Wolf PA. Genomewide association studies of stroke. N Engl J Med. 2009;360:1718 1728. 72. International Stroke Genetics Consortium; Wellcome Trust Case-Control Consortium 2. Failure to validate association between 12p13 variants and ischemic stroke. N Engl J Med. 2010;362:1547 1550. 73. Olsson S, Melander O, Jood K, Smith JG, Lovkvist H, Sjogren M, Engstrom G, Norrving B, Lindgren A, Jern C; International Stroke Genetics Consortium (ISGC). Genetic variant on chromosome 12p13 does not show association to ischemic stroke in 3 Swedish case-control studies. Stroke. 2011;42:214 216. 74. HsiehYC, Seshadri S, Chung WT, Hsieh FI, HsuYH, Lin HJ, Tseng HP, Lien LM, Bai CH, Hu CJ, Jeng JS, Tang SC, Chen CI, Yu CC, Chiou HY; Formosa Stroke Genetic Consortium (FSGC).


HsiehYC, Seshadri S, Chung WT, Hsieh FI, HsuYH, Lin HJ, Tseng HP, Lien LM, Bai CH, Hu CJ, Jeng JS, Tang SC, Chen CI, Yu CC, Chiou HY; Formosa Stroke Genetic Consortium (FSGC). Association between genetic variant on chromosome 12p13 and stroke survival and recur- rence: a one year prospective study in Taiwan. J Biomed Sci. 2012;19:1. 75. Holliday EG, Maguire JM, Evans TJ, Koblar SA, Jannes J, Sturm JW, Hankey GJ, Baker R, Golledge J, Parsons MW, Malik R, McEvoy M, Biros E, Lewis MD, Lincz LF, Peel R, Oldmeadow C, Smith W, Moscato P, Barlera S, Bevan S, Bis JC, Boerwinkle E, Boncoraglio GB, Brott TG, Brown RD Jr, Cheng YC, Cole JW, Cotlarciuc I, Devan WJ, Fornage M, Furie KL, Gretarsdottir S, Gschwendtner A, Ikram MA, Longstreth WT Jr, Meschia JF, Mitchell BD, Mosley TH, Nalls MA, Parati EA, Meschia et al Guidelines for the Primary Prevention of Stroke 3809 Psaty BM, Sharma P, Stefansson K, Thorleifsson G, Thorsteinsdottir U, Traylor M, Verhaaren BF, Wiggins KL, Worrall BB, Sudlow C, Rothwell PM, Farrall M, Dichgans M, Rosand J, Markus HS, Scott RJ, Levi C, Attia J; Australian Stroke Genetics Collaborative; International Stroke Genetics Consortium; Wellcome Trust Case Control Consortium 2. Common variants at 6p21.1 are associated with large artery atheroscle- rotic stroke. Nat Genet. 2012;44:1147 1151.


Common variants at 6p21.1 are associated with large artery atheroscle- rotic stroke. Nat Genet. 2012;44:1147 1151. 76. International Stroke Genetics Consortium (ISGC); Wellcome Trust Case Control Consortium 2 (WTCCC2), Bellenguez C, Bevan S, Gschwendtner A, Spencer CC, Burgess AI, Pirinen M, Jackson CA, Traylor M, Strange A, Su Z, Band G, Syme PD, Malik R, Pera J, Norrving B, Lemmens R, Freeman C, Schanz R, James T, Poole D, Murphy L, Segal H, Cortellini L, Cheng YC, Woo D, Nalls MA, Muller-Myhsok B, Meisinger C, Seedorf U, Ross-Adams H, Boonen S, Wloch-Kopec D, Valant V, Slark J, Furie K, Delavaran H, Langford C, Deloukas P, Edkins S, Hunt S, Gray E, Dronov S, Peltonen L, Gretarsdottir S, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boncoraglio GB, Parati EA, Attia J, Holliday E, Levi C, Franzosi MG, Goel A, Helgadottir A, Blackwell JM, Bramon E, Brown MA, Casas JP, CorvinA, DuncansonA, Jankowski J, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Worrall BB, Kittner SJ, Mitchell BD, Kissela B, Meschia JF, ThijsV, LindgrenA, Macleod MJ, SlowikA,Walters M, Rosand J, Sharma P, Farrall M, Sudlow CL, Rothwell PM, Dichgans M, Donnelly P, Markus HS. Genome-wide association study identifies a variant in HDAC9 asso- ciated with large vessel ischemic stroke. Nat Genet. 2012;44:328 333. 77.


Genome-wide association study identifies a variant in HDAC9 asso- ciated with large vessel ischemic stroke. Nat Genet. 2012;44:328 333. 77. Traylor M, Farrall M, Holliday EG, Sudlow C, Hopewell JC, ChengYC, Fornage M, Ikram MA, Malik R, Bevan S, Thorsteinsdottir U, Nalls MA, Longstreth W, Wiggins KL, Yadav S, Parati EA, Destefano AL, Worrall BB, Kittner SJ, Khan MS, Reiner AP, Helgadottir A, Achterberg S, Fernandez-Cadenas I, Abboud S, Schmidt R, Walters M, Chen WM, Ringelstein EB, O Donnell M, Ho WK, Pera J, Lemmens R, Norrving B, Higgins P, Benn M, Sale M, Kuhlenbaumer G, Doney AS, Vicente AM, Delavaran H, Algra A, Davies G, Oliveira SA, Palmer CN, Deary I, Schmidt H, Pandolfo M, Montaner J, Carty C, de Bakker PI, Kostulas K, Ferro JM, van Zuydam NR, Valdimarsson E, Nordestgaard BG, Lindgren A, Thijs V, Slowik A, Saleheen D, Pare G, Berger K, Thorleifsson G; Australian Stroke Genetics Collaborative, Wellcome Trust Case Control Consortium 2 (WTCCC2), Hofman A, Mosley TH, Mitchell BD, Furie K, Clarke R, Levi C, Seshadri S, Gschwendtner A, Boncoraglio GB, Sharma P, Bis JC, Gretarsdottir S, Psaty BM, Rothwell PM, Rosand J, Meschia JF, Stefansson K, Dichgans M, Markus HS; International Stroke Genetics Consortium. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11:951 962. 78. Li J, Luo M, Xu X, Sheng W. Association between 1425G/A SNP in PRKCH and ischemic stroke among Chinese and Japanese populations: a meta-analysis including 3686 cases and 4589 controls. Neurosci Lett. 2012;506:55 58. 79. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der ZeeAH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group.


Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der ZeeAH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. A ran- domized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013;369:2294 2303. 80. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013;369:2283 2293. 81. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med. 2013;369:2304 2312. 82. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 vari- ants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008;359:789 799. 83. Tournier-Lasserve E, Joutel A, Chabriat H, Vahedi K, Nagy T, Ducros A, Nibbio A, Verin M, Mas JL, Davous P, Ducrocq X, Levasseur M, Dubois B, Lyoncaen O, Ragno M, Hutchinson M, Burkhard P, Julien J, Viader F, Burgunder JM, Iba-Zizen MT, Bousser MG. CADASIL Clinical phe- notypes and genetic data in 15 unrelated families. Neurology. 1995;45(4 Suppl 4):A273. 84.


Tournier-Lasserve E, Joutel A, Chabriat H, Vahedi K, Nagy T, Ducros A, Nibbio A, Verin M, Mas JL, Davous P, Ducrocq X, Levasseur M, Dubois B, Lyoncaen O, Ragno M, Hutchinson M, Burkhard P, Julien J, Viader F, Burgunder JM, Iba-Zizen MT, Bousser MG. CADASIL Clinical phe- notypes and genetic data in 15 unrelated families. Neurology. 1995;45(4 Suppl 4):A273. 84. Kalimo H, Viitanen M, Amberla K, Juvonen V, Marttila R, Poyhonen M, Rinne JO, Savontaus M, Tuisku S, Winblad B. CADASIL: hereditary disease of arteries causing brain infarcts and dementia. Neuropathol Appl Neurobiol. 1999;25:257 265. 85. Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, Liszewski MK, Barilla-Labarca ML, Terwindt GM, Kasai Y, McLellan M, Grand MG, Vanmolkot KR, de Vries B, Wan J, Kane MJ, Mamsa H, Schafer R, Stam AH, Haan J, de Jong PT, Storimans CW, van Schooneveld MJ, Oosterhuis JA, GschwendterA, Dichgans M, Kotschet KE, Hodgkinson S, Hardy TA, Delatycki MB, Hajj-Ali RA, Kothari PH, Nelson SF, Frants RR, Baloh RW, Ferrari MD, Atkinson JP. C-terminal truncations in human 3 -5 DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39:1068 1070. bral small vessel disease: a systematic review. Stroke. 2010;41:e513 e518. 87. Alamowitch S, Plaisier E, Favrole P, Prost C, Chen Z, Van Agtmael T, Marro B, Ronco P. Cerebrovascular disease related to COL4A1 muta- tions in HANAC syndrome. Neurology. 2009;73:1873 1882. 88. Desnick R, Ioannou Y, Eng C. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beauder AL, Sly WS, Childs B, Valle D, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001:3733 3774. 89. De Schoenmakere G, Chauveau D, Grunfeld JP. Enzyme replacement therapy in Anderson-Fabry s disease: beneficial clinical effect on vital organ function.


Enzyme replacement therapy in Anderson-Fabry s disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant. 2003;18:33 35. 90. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ; International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry s disease. N Engl J Med. 2001;345:9 16. 91. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743 2749. 92. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE. 2007;2:e598. 93. Ortel T. Genetics of coagulation disorders. In: Alberts M, ed. Genetics of Cerebrovascular Disease.Armonk, NY: Futura Publishing; 1999:129 156. 94. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagula- tion factor V associated with resistance to activated protein C. Nature. 1994;369:64 67. 95. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, Samama MM, Bousser MG. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 1996;27:1724 1730. 96. Hillier CE, Collins PW, Bowen DJ, Bowley S, Wiles CM. Inherited prothrombotic risk factors and cerebral venous thrombosis. QJM. 1998;91:677 680. 97. Kuwahara S, Abe T, Uga S, Mori K. Superior sagittal sinus and cerebral cortical venous thrombosis caused by congenital protein C deficiency: case report. Neurol Med Chir (Tokyo). 2000;40:645 649. 98. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI.


Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke. 2001;32:1793 1799. 99. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100:3 10. 100. Weber M, Hayem G, DeBandt M, Palazzo E, Roux S, Kahn MF, Meyer O. The family history of patients with primary or secondary antiphos- pholipid syndrome (APS). Lupus. 2000;9:258 263. 101. Goldberg SN, Conti-Kelly AM, Greco TP. A family study of anti- cardiolipin antibodies and associated clinical conditions. Am J Med. 1995;99:473 479. 102. Acharya SS. Rare bleeding disorders in children: identification and pri- mary care management. Pediatrics. 2013;132:882 892. 103. Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol. 2000;12:41 47. 104. Shetty-Alva N, Alva S. Familial moyamoya disease in Caucasians. Pediatr Neurol. 2000;23:445 447. 105. Grantham JJ. Clinical practice: autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359:1477 1485. 106. Cloft HJ, Kallmes DF, Kallmes MH, Goldstein JH, Jensen ME, Dion JE. Prevalence of cerebral aneurysms in patients with fibromuscular dyspla- sia: a reassessment. J Neurosurg. 1998;88:436 440. 107. Germain DP. Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis. 2007;2:32. 108. Fischer A, Zalvide J, Faurobert E, Albiges-Rizo C, Tournier-Lasserve E. Cerebral cavernous malformations: from CCM genes to endothelial cell homeostasis. Trends Mol Med. 2013;19:302 308. 109. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, Frangione B. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002;12:343 357. 110.


Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002;12:343 357. 110. Bederson JB, Awad IA, Wiebers DO, Piepgras D, Haley EC Jr, Brott T, Hademenos G, Chyatte D, Rosenwasser R, Caroselli C. Recommendations for the management of patients with unruptured intracranial aneurysms: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation. 2000;102:2300 2308. 111. US Department of Health and Human Services. 2008 Physical activ- ity guidelines for Americans. http://www.health.gov/paguidelines/. Accessed February 27, 2013. 112. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta- analysis. Stroke. 2003;34:2475 2481. 113. Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, Kromhout D. Physical activity and stroke: a meta-anal- ysis of observational data. Int J Epidemiol. 2004;33:787 798. 114. Gillum RF, Mussolino ME, Ingram DD. Physical activity and stroke incidence in women and men: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1996;143:860 869. 115. Sacco RL, Gan R, Boden-Albala B, Lin IF, Kargman DE, Hauser WA, Shea S, Paik MC. Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. Stroke. 1998;29:380 387. 116. Grau AJ, Ling P, Palm F, Urbanek C, Becher H, Buggle F. Childhood and adult social conditions and risk of stroke. Cerebrovasc Dis. 2012;33:385 391. 117. Willey JZ, Moon YP, Paik MC, Boden-Albala B, Sacco RL, Elkind MS. Physical activity and risk of ischemic stroke in the Northern Manhattan Study. Neurology. 2009;73:1774 1779. 118. Willey JZ, Moon YP, Paik MC, Yoshita M, Decarli C, Sacco RL, Elkind MS,Wright CB. Lower prevalence of silent brain infarcts in the physically active: the Northern Manhattan Study. Neurology. 2011;76:2112 2118. 119. Williams PT. Reduction in incident stroke risk with vigorous physical activity: evidence from 7.7-year follow-up of the National Runners Health Study. Stroke. 2009;40:1921 1923. 120.


Reduction in incident stroke risk with vigorous physical activity: evidence from 7.7-year follow-up of the National Runners Health Study. Stroke. 2009;40:1921 1923. 120. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141 1147. 121. Blair SN, Kampert JB, Kohl HW 3rd, Barlow CE, Macera CA, Paffenbarger RS Jr, Gibbons LW. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA. 1996;276:205 210. 122. Kokkinos PF, Holland JC, Pittaras AE, Narayan P, Dotson CO, Papademetriou V. Cardiorespiratory fitness and coronary heart disease risk factor association in women. J Am Coll Cardiol. 1995;26:358 364. 123. Lakka TA, Salonen JT. Moderate to high intensity conditioning lei- sure time physical activity and high cardiorespiratory fitness are asso- ciated with reduced plasma fibrinogen in eastern Finnish men. J Clin Epidemiol. 1993;46:1119 1127. 124. Wang HY, Bashore TR, Friedman E. Exercise reduces age-depen- dent decrease in platelet protein kinase C activity and translocation. J Gerontol A Biol Sci Med Sci. 1995;50A:M12 M16. 125. Williams PT. High-density lipoprotein cholesterol and other risk fac- tors for coronary heart disease in female runners. N Engl J Med. 1996;334:1298 1303. 126. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P. Position statement, part one: immune function and exercise. Exerc Immunol Rev. 2011;17:6 63. 127. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TW, Yanovski SZ.


Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey LP, Wadden TW, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle management to reduce cardio- vascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S76 S99. 128. Sacco RL, Khatri M, RundekT, Xu Q, Gardener H, Boden-Albala B, DiTullio MR, Homma S, Elkind MS, Paik MC. Improving global vascular risk pre- diction with behavioral and anthropometric factors: the multiethnic NOMAS (Northern Manhattan Cohort Study). J Am Coll Cardiol. 2009;54:2303 2311. 129. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989;320:904 910. 130. Leppala JM,Virtamo J, Fogelholm R,Albanes D, Heinonen OP. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke. 1999;30:2535 2540. 131. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, MacMahon S, Woodward M; Asia Pacific Cohort Studies Collaboration. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563 572. 132. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortal- ity in the Women s Pooling Project. Stroke. 2002;33:1863 1868. 133. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology. 2007;68:556 562. 134. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, SharrettAR;Atherosclerosis Risk in Communities Study. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003;34:623 631. 135.


Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2003;34:623 631. 135. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled pro- spective study. Stroke. 2007;38:2718 2725. 136. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, Izumi Y, Ohta H. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation. 2009;119:2136 2145. 137. Iribarren C, Jacobs DR, Sadler M, ClaxtonAJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association con- fined to elderly men? The Kaiser Permanente Medical Care Program. Stroke. 1996;27:1993 1998. 138. Cui R, Iso H, Toyoshima H, Date C, Yamamoto A, Kikuchi S, Kondo T, Watanabe Y, Koizumi A, Inaba Y, Tamakoshi A; JACC Study Group. Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese: the JACC study. Atherosclerosis. 2007;194:415 420. 139. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cho- lesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet. 2001;357:922 925. 140. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829 1839. 141. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovas- cular disease: the Copenhagen City Heart Study. BMJ. 1994;309:11 15. 142. Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H; Oyabe Study.


Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H; Oyabe Study. High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: the Oyabe Study. Stroke. 2003;34:863 868. 143. Tanne D,Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality: a 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke. 1997;28:83 87. 144. Wannamethee SG, Shaper AG, Ebrahim S. HDL-cholesterol, total cholesterol, and the risk of stroke in middle-aged British men. Stroke. 2000;31:1882 1888. 145. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, Cheng JF, Paik MC, Shea S, Berglund L. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001;285:2729 2735. P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipo- proteins, and risk of vascular disease. JAMA. 2009;302:1993 2000. 147. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Gaziano JM. Cholesterol and the risk of ischemic stroke. Stroke. 2003;34:2930 2934. 148. Haheim LL, Holme I, Hjermann I, Leren P. Risk factors of stroke inci- dence and mortality: a 12-year follow-up of the Oslo Study. Stroke. 1993;24:1484 1489. Meschia et al Guidelines for the Primary Prevention of Stroke 3811 149. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M; Asia Pacific Cohort Studies Collaboration. Serum tri- glycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678 2686. 150. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general popu- lation. JAMA. 2008;300:2142 2152. 151. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM.


Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309 316. 152. Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regres- sion analysis. Atherosclerosis. 2010;212:9 15. 153. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke pre- vention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902 2909. 154. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lower- ing treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267 1278. 155. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453 463. 156. Chan DK, O Rourke F, Shen Q, Mak JC, Hung WT. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand. 2011;124:188 195. 157. Mills EJ, O Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J. 2011;32:1409 1415. 158. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, KeechA, Simes J, Barnes EH,Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581 590. 159.


Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, KeechA, Simes J, Barnes EH,Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581 590. 159. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N, Manns B; Alberta Kidney Disease Network. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011;183:E1189 1202. 160. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121:143 150. 161. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43:2149 2156. 162. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemor- rhage: collaborative systematic review and meta-analysis. Circulation. 2011;124:2233 2242. 163. Bedi US, Singh M, Singh PP, Bhuriya R, Bahekar A, Molnar J, Khosla S, Arora R. Effects of statins on progression of carotid atheroscle- rosis as measured by carotid intimal-medial thickness: a meta-anal- ysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2010;15:268 273. 164. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O Leary DH, Grobbee DE, Bots ML; METEOR Study Group.


Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosu- vastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344 1353. 165. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lower- ing on atherosclerosis progression in familial hypercholesterolae- mia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357:577 581. 166. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055 2060. 167. Zhao XQ, Dong L, Hatsukami T, Phan BA, Chu B, Moore A, Lane T, Neradilek MB, Polissar N, Monick D, Lee C, Underhill H, Yuan C. MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging. 2011;4:977 986. 168. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, Warburton EA, Hayes PD, Varty K, Boyle JR, Gaunt ME, Zalewski A, Gillard JH. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: evaluation using ultrasmall superparamag- netic iron oxide-enhanced magnetic resonance imaging in carotid dis- ease. J Am Coll Cardiol. 2009;53:2039 2050. 169. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW.


Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1 S45. 170. De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, Tatasciore A, Marchioli R. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2010;55:198 211. 171. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245 1255. 172. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiv- ing intensive statin therapy. N Engl J Med. 2011;365:2255 2267. 173. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61:440 446. cebo-controlled trial in 25 673 high-risk patients of ER niacin/laropip- rant: trial design, pre-specified muscle, and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279 1291. 175. Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coro- nary artery disease. Circulation. 2000;102:21 27. 176. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ; VA-HIT Study Group.